Abstract: A method of increasing viscosity of a pharmaceutical formulation for oral or topical administration comprises the steps of combining: a. an effective amount of one or more hydrophobic active ingredients; b. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids of formula (1) CH2OR—CHOR—CH20-[CH2CHOR—CH2O—]NCH2—CHOR—CH2OR??(1) wherein n is an integer from 4 to 13 and R is H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen; c. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2) CH2OR—CHOR—CH20-[CH2CHOR—CH2O]NCH2—CHOR—CH2OR??(2) wherein n is an integer from 0 to 10 and R?H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen; d.

Abstract: Pharmaceutical compositions especially for internal application which create lyotropic liquid crystals when in contact with aqueous phase. The pharmaceutical compositions consist of: A hydrophobic active ingredient with immunomodulatory effect from a group of N-methylated cyclic undecapeptides or macrolide antibiotics, in quantity 1-35 weight % in a carrier medium containing B at least one absorption promoter allowing for contact of the drug with a biological membrane or passing of the drug through in quantity 1-40 weight %, C nonlipidic vehicle containing at lest one of the below mentioned substances: C1 surfactant or mixed surfactant with HLB>9, in quantity 1-80 weight % C2 lipophilic solvent from group of higher fatty alcohols in quantity 1-30 weight % C3 at least one cosurfactant in quantity 1-50 weight %, while a ratio among the individual components of the product is A:B:C=1:0.5-4:5-8.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Therapeutical compositions comprising from 0.1 to 20% by weight of a cyclosporin and a vehicle comprising from 1 to 60% by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide, and from 1 to 60% by weight of a mixture of glyceryl monoesters of C.sub.8 -C.sub.22 fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C.sub.8 -C.sub.22 fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilizers, flavoring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.

Abstract: This invention relates to a method for the treatment of endometritis (chronic and/or acute puerperal inflammations) in mammalian females comprising the administration of 1-(8-alpha-ergolinyl)-3,3-diethylurea derivatives of Formula I ##STR1## in which R.sup.1 represents an alkyl group containing 1 to 3 carbon atoms, R.sup.2 represents a hydrogen atom or an alkyl group containing 1 to 3 carbon atoms, and X represents a hydrogen atom or a double bond between the carbon atoms at positions 9 and 10. The compound according to Formula I, or a pharmaceutically acceptable acid addition salt thereof, is the physiologically active component of the therapeutic composition and method. The compound may be combined with a pharmaceutically acceptable diluent, vehicle, excipient, auxiliary, or carrier. The invention is particularly advantageous in veterinary medicine, when applied to the treatment of farm animals, such a cows.